<HTML>
<HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
<BODY>

<P ALIGN=CENTER><FONT SIZE=3><B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
                                       Washington, D.C. 20549</FONT></P>

<P ALIGN=CENTER><FONT SIZE=3><B>FORM 8-K</B></FONT></P><BR>

<P ALIGN=CENTER><FONT SIZE=3><B>CURRENT REPORT</B></FONT></P><BR>

<P ALIGN=CENTER><FONT SIZE=3><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></FONT></P>

<P><FONT SIZE=3>Date of Report (date of earliest event reported): July 19, 2001.</FONT></P><BR>



<P ALIGN=CENTER><FONT SIZE=3><B>                     BioTime, Inc.</B></FONT><BR>
<FONT SIZE=2>                             (Exact name of registrant as specified in its charter)</FONT></P><BR>

<P><FONT SIZE=3><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;California&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
1-12830&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;94-3127919</B></FONT><BR>
<FONT SIZE=2>(State or other jurisdiction of incorporation or organization)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Commission File Number)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(IRS Employer Identification No.)</FONT></P>


<P ALIGN=CENTER><FONT SIZE=3><B>935 Pardee Street<BR>
                                Berkeley, California 94710</B></FONT><BR>
<FONT SIZE=2>(Address of principal executive offices)</FONT></P>

<P ALIGN=CENTER><FONT SIZE=3><B>                             (510) 845-9535</B></FONT><BR>
                    <FONT SIZE=2>(Registrant's telephone number, including area code)</FONT></P>


<PAGE>


<P><FONT FACE="Times New Roman, Times, Serif" SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements
made in this Report that are not historical facts may constitute forward-
looking statements that are subject to risks and uncertainties that could cause
actual results to differ materially from those discussed. Such risks and
uncertainties include but are not limited to those discussed in this report and
in BioTime&#146;s Annual Report on Form 10-K filed with the Securities and
Exchange Commission. Words such as &#147;expects,&#148; &#147;may,&#148;
&#147;will,&#148; &#147;anticipates,&#148; &#147;intends,&#148;
&#147;plans,&#148; &#147;believes,&#148; &#147;seeks,&#148;
&#147;estimates,&#148; and similar expressions identify forward- looking
statements. </FONT></P>

<H4>Item 5.  Other Events.</H4>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
July 19, 2001 BioTime, Inc. was informed by Horus, B.V. (a subsidiary of Akzo Nobel, N.V) that Horus will not finalize the
supply and manufacturing agreements contemplated by the Exclusive License Agreement signed by the parties during
February 2001. Horus&#146; obligations under the License Agreement are conditioned upon certain manufacturing and supply
arrangements, which have not been completed. BioTime's obligations under the License Agreement are conditioned upon its
receipt of an initial license fee, which has not been paid by Horus. Accordingly, Horus will not market Hextend or
other BioTime products under that license agreement and BioTime will offer those rights to other pharmaceutical
companies. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
development follows a major reorganization of Akzo Nobel&#146;s pharmaceutical divisions. BioTime is reopening
discussions with other companies that have expressed their interest in marketing BioTime&#146;s product
line in Europe and other parts of the world. </FONT></P>

                                 <P ALIGN=CENTER>2</P><BR><BR>


<P ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=3><B>SIGNATURES</B></FONT></P><BR>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized. </FONT></P>

<H4>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BIOTIME, INC.</H4>


<P><FONT FACE="Times New Roman, Times, Serif" SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/Paul E. Segall<BR>

Date: July 26, 2001&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By ______________________________________<BR>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paul E. Segall,<BR>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chairman and Chief Executive Officer</FONT></P>









                             <P ALIGN=CENTER>3</P><BR><BR>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "form8kterm_072001.htm", "description": "FORM 8-K", "secsgml_size_bytes": 8156}]
{"company-data": {"conformed-name": "BIOTIME INC", "cik": "0000876343", "assigned-sic": "2836", "irs-number": "943127919", "state-of-incorporation": "CA", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-12830", "film-number": "1689643"}, "business-address": {"street1": "935 PARDEE ST", "city": "BERKELEY", "state": "CA", "zip": "94710", "phone": "5108459535"}, "mail-address": {"street1": "935 PARDEE STREET", "city": "BERKELEY", "state": "CA", "zip": "94710"}}
Form 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 19, 2001.
BioTime, Inc.
(Exact name of registrant as specified in its charter)
California     
                      
                            
                       
                  
1-12830                
                         
             94-3127919
(State or other jurisdiction of incorporation or organization)           
                       
                  (Commission File Number)
     
                       
             (IRS Employer Identification No.)
935 Pardee Street
Berkeley, California 94710
(Address of principal executive offices)
(510) 845-9535
(Registrant's telephone number, including area code)
Statements
made in this Report that are not historical facts may constitute forward-
looking statements that are subject to risks and uncertainties that could cause
actual results to differ materially from those discussed. Such risks and
uncertainties include but are not limited to those discussed in this report and
in BioTime's Annual Report on Form 10-K filed with the Securities and
Exchange Commission. Words such as "expects," "may,"
"will," "anticipates," "intends,"
"plans," "believes," "seeks,"
"estimates," and similar expressions identify forward- looking
statements.
Item 5.  Other Events.
On
July 19, 2001 BioTime, Inc. was informed by Horus, B.V. (a subsidiary of Akzo Nobel, N.V) that Horus will not finalize the
supply and manufacturing agreements contemplated by the Exclusive License Agreement signed by the parties during
February 2001. Horus' obligations under the License Agreement are conditioned upon certain manufacturing and supply
arrangements, which have not been completed. BioTime's obligations under the License Agreement are conditioned upon its
receipt of an initial license fee, which has not been paid by Horus. Accordingly, Horus will not market Hextend or
other BioTime products under that license agreement and BioTime will offer those rights to other pharmaceutical
companies.
This
development follows a major reorganization of Akzo Nobel's pharmaceutical divisions. BioTime is reopening
discussions with other companies that have expressed their interest in marketing BioTime's product
line in Europe and other parts of the world.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
BIOTIME, INC.
/s/Paul E. Segall
Date: July 26, 2001          
                      
            By ______________________________________
Paul E. Segall,
Chairman and Chief Executive Officer
3